All AbMole products are for research use only, cannot be used for human consumption.
Darbufelone (CI-1004) is a dual inhibitor of cellular PGF2α and LTB4 production, it is also a COX-2 inhibitor potentially for the treatment of rheumatoid arthritis. Darbufelone potently inhibits PGHS-2 (IC50=0.19 μM) but is much less potent with PGHS-1 (IC50=20 μM). The IC50 of A549 and H520 are 20±3.6 and 21±1.8 μM, respectively, while the H460 has much lower IC50 (15±2.7 μM).
Darbufelone is orally active and nonulcerogenic in animal models of inflammation and arthritis. The tumor volumes decrease in a time-dependent manner on mice treated with Darbufelone (80 mg/kg/day). In contrast, lower dose of Darbufelone (20 or 40 mg/kg/day) dos not show any significant inhibition of tumor weight. At necropsy, the tumor weight in mice treated with Darbufelone (80 mg/kg/day) is reduced by 30.2% in comparison with control group.
| Cell Experiment | |
|---|---|
| Cell lines | A549, NCI-H520 and NCI-H460 cells |
| Preparation method | In brief, tumor cells growing in log-phase are trypsinized and seeded at 5×103 cells per well into 96-well plates and allowed to attach overnight. Medium in each well is replaced with fresh medium or medium containing various concentrations of Darbufelone (5-60 μM) in at least triplicate wells. Cells are cultured to another 72 h. After treatment, 1/10 volume of MTT solution (5 mg/mL) is added to each well, and the plate is incubated at 37°C for another 4 h. Two hundred microliters of DMSO is added to each well to solubilize the MTT-formazan product after removal of the medium. Absorbance at 595 nm is measured with a multi-well spectrophotometer. Growth inhibition is calculated as a percentage of the untreated controls. |
| Concentrations | 5-60 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | C57Bl/6 male mice implanted Lewis Lung Carcinoma cells |
| Formulation | CMC-Na |
| Dosages | 20, 40, and 80 mg/kg/day |
| Administration | gavage |
| Molecular Weight | 332.46 |
| Formula | C18H24N2O2S |
| CAS Number | 139226-28-1 |
| Storage | -20°C, dry, sealed |
| Related Prostaglandin Receptor Products |
|---|
| Prostaglandin D2
Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. PGD2 plays a protective role by suppressing inflammation. |
| Tafluprost acid
Tafluprost acid (AFP-172) is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. |
| TG8-260
TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. |
| Camonagrel
Camonagrel is a compound that has inhibitory effects on Prostaglandin E2. |
| BAY 73-1449
BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
